TICKERNERD
Menu
ANVSANVSHealthcare · Biotechnology

ANVS Stock Forecast: Annovis Bio, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.81
+1.12% on the day

The 3 Wall Street analysts covering Annovis Bio, Inc. hold a median 12-month price target of $8 — +342.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$77.1M
Ticker Nerd rank
26 / 100
Median analyst target
$8.00
Analysts covering
3
Total return, dividends reinvested
1W
−2.2%
1M
+3.4%
YTD
−47.7%
1Y
−23.9%
From 52W high
−64.5%
From 52W low
+13.8%
$1.59
$5.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Annovis Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
78
Accruals
66
Revisions
65
Quality
29
Issuance
27
Value
23
Growth
23
Volatility
20
Momentum
18

Size (78): Smaller than most of the companies we track.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26ANVSHigh $17.00Median $8.00Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $8.00Median $8.00High $17.00

The green dot is the last close — the median target sits +342.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026Canaccord GenuityMaintainsBuy$17
8 July 2026Roth CapitalInitiatesBuy$8.00
8 July 2026Roth CapitalInitiatesBuy—
14 Apr 2026Canaccord GenuityMaintainsBuy—
30 Sept 2025Canaccord GenuityMaintainsBuy—
3 Sept 2025HC Wainwright & Co.MaintainsBuy—
9 June 2025HC Wainwright & Co.MaintainsBuy—
15 May 2025Canaccord GenuityMaintainsBuy—
10 Feb 2025D. Boral CapitalDowngradeHold—
11 Nov 2024D. Boral CapitalMaintainsBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
25 Oct 2024Maxim GroupUpgradeBuy—
16 Oct 2024HC Wainwright & Co.ReiteratesBuy$30
15 Oct 2024EF HuttonMaintainsBuy$21
1 Oct 2024HC Wainwright & Co.ReiteratesBuy$30
15 Aug 2024EF HuttonMaintainsBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024EF HuttonInitiatesBuy—
17 July 2024HC Wainwright & Co.ReiteratesBuy—
11 July 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ANVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Annovis Bio, Inc. (ANVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
16.2×

Cheaper than 7% of US stocks

EV / EBITDA
−1.9×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−703.7%

Higher than 2% of US stocks

Return on assets
−142.4%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ANVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANVSAnnovis Bio, Inc.$77.1M
26
TELOTelomir Pharmaceuticals, Inc.$77.7M
13
NRXSNeurAxis, Inc.$76.2M
54
GOSSGossamer Bio, Inc.$75.6M
54
ELTXElicio Therapeutics, Inc.$79.9M
38
CINGCingulate, Inc.$80.7M
28
SERSerina Therapeutics, Inc.$72.9M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Annovis Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANVS news & analysis

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

GlobeNewsWire · 14 Aug 2026neutral

Annovis Bio, Inc. provided business updates and reported financial results for the second quarter ended June 30, 2026. The Phase 3 clinical-stage biotechnology company is developing the oral investigational therapy buntanetap for neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

Why it matters — The release updates ANVS watchers on the company's latest operational progress and Q2 2026 financial performance.

FAQ

Frequently asked questions about ANVS stock

What is the ANVS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Annovis Bio, Inc. have a median 12-month price target of $8, with estimates ranging from $8 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANVS stock a buy right now?

Of the 3 analysts covering Annovis Bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Annovis Bio, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANVS?

As at 22 Aug 2026, Annovis Bio, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).

Will ANVS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +342.0% from the last close, and Ticker Nerd's factor model ranks Annovis Bio, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANVS stock forecast for 2030?

No analyst covering Annovis Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $17 over the next 12 months.

How has ANVS stock performed over the past year?

Annovis Bio, Inc. returned -23.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Annovis Bio, Inc. do?

Annovis Bio, Inc. is a biopharmaceutical company committed to developing novel therapeutic solutions for neurodegenerative diseases.

What is the latest news on ANVS?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results". Annovis Bio, Inc. provided business updates and reported financial results for the second quarter ended June 30, 2026. The Phase 3 clinical-stage biotechnology company is developing the oral investigational therapy buntanetap for neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

Company

About Annovis Bio, Inc.

Annovis Bio, Inc. is a biopharmaceutical company committed to developing novel therapeutic solutions for neurodegenerative diseases. At the core of its operations is the design of drugs aiming to inhibit neurotoxic protein buildup associated with conditions like Alzheimer's and Parkinson's disease. By targeting the underlying biochemical pathways that lead to such diseases, Annovis Bio seeks to address the cognitive and functional impairments that characterize these neurological disorders. Their focus on creating drugs that have the potential to halt or reverse disease progression places Annovis Bio at the forefront of groundbreaking biomedical research. With these advancements, Annovis Bio is positioned within the specialized biotechnology sector, catering to a critical need in the healthcare market for more effective and innovative treatments. Its contributions are particularly significant as the global demand for solutions for neurodegenerative ailments continues to rise, highlighting its role as an important player in the intersection of health sciences and pharmaceutical innovation.

CEO Dr. Maria L. Maccecchini Ph.D. · 8 employees · United States · https://www.annovisbio.com